{"id":"NCT01179217","sponsor":"Emmaus Medical, Inc.","briefTitle":"A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia","officialTitle":"A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2010-08-11","resultsPosted":"2017-08-10","lastUpdate":"2020-08-19"},"enrollment":230,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Sickle Cell Anemia","Sickle ß0-Thalassemia"],"interventions":[{"type":"DRUG","name":"L-glutamine","otherNames":["oral L-glutamine"]},{"type":"DRUG","name":"Placebo","otherNames":["Maltodextrin"]}],"arms":[{"label":"L-glutamine","type":"EXPERIMENTAL"},{"label":"100% maltodextrin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this research is to evaluate the effects of L-glutamine as a therapy for Sickle Cell Anemia or Sickle ß0 Thalassemia as evaluated by the number of occurrences of sickle cell crises.","primaryOutcome":{"measure":"The Number of Occurrences of Sickle Cell Crises","timeFrame":"48 weeks","effectByArm":[{"arm":"L-glutamine","deltaMin":3,"sd":null},{"arm":"100% Maltodextrin","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0052"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["38775255","30021096"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":118,"n":151},"commonTop":["Sickle cell anaemia with crisis","Pyrexia","Constipation","Nausea","Headache"]}}